BioNotebook: Savient, Vital Therapies and Arrowhead
This article was originally published in Scrip
Executive Summary
Savient Pharmaceuticals will liquidate under Chapter II bankruptcy; Vital Therapies seeks $86.25m initial public offering; and Arrowhead Research raises $60m.